The medical community is in the midst of an unprecedented transformation driven by the establishment of precision medicine. Until now, most medical treatments have been designed for the average patient. Under this one-size-fits-all approach, treatments can be successful for some patients but not for others. On the other hand, precision medicine is an innovative approach that takes into account individual differences in people's genes, environments, and lifestyles.

As such, an era of next generation diagnostics and personalized therapies as new armamentarium against unrelenting disease has begun. Specifically, the genomic and proteomic biomarkers of a disease have a deterministic role in the disease progression and management. Non-invasive and real-time interrogation of these biomarkers in cell-free and cell-based constituents of a biological sample is critical to the patient's clinical outcome. This is the premise on which Abnova Diagnostics is founded. Sophisticated, analytical platforms and application-driven bio-reagents are integrated to identify clinically-relevant biomarkers in circulating tumor cells, fetal cells, and exosomes in blood and in tissue. These actionable biomarkers are translated to detect early disease and metastasis, guide therapy, maximize treatment response, minimize drug resistance and recurrence.

Abnova Diagnostics, established on April 8th, 2015, is a subsidiary company of Abnova Corporation, the largest antibody manufacturer in the world. With the technological supports from Abnova Corporation, Abnova Diagnostics is at the technological forefront of in vitro diagnostic transformation of precision medicine. We have built a valuable network of academic, clinical, industrial partners and experts. By leveraging these resources, we aim to empower investigators, patients, and providers to work together toward the development and delivery of personalized medicine for the individual patient.

©2017 Abnova Diagnostics. All rights reserved.